Ozone-induced increases in substance P and 8-epi-prostaglandin F2 alpha in the airways of human subjects.
We are interested in the mechanisms of ozone-induced lung effects after short-term exposure and the relationship with subsequent pulmonary inflammation and disease. Our hypothesis is that ozone, as a powerful oxidant, will diminish the activity of neutral endopeptidase (NEP) in the airways of humans with resulting increased concentrations of neuropeptides such as substance P (SP). We have exposed seven (two women, five men) healthy, nonsmoking individuals (22 to 30 yr of age) to filtered air and ozone (0.25 ppm) for 1 h in an environmental chamber during heavy exercise. Bronchoscopy with airway lavage (AL) and bronchoalveolar lavage (BAL) was performed immediately after ozone exposure. The lavage samples were analyzed by enzyme immunoassay for SP and 8-epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) (a marker for oxidative free radical reaction) and by radioimmunoassay for complement fragments. FEV1 had declined 12.4 +/- 1.9% (mean +/- SEM) as a result of ozone exposure. The AL concentration for SP and 8-epi-PGF2 alpha and BAL concentration of C3a after ozone exposure were significantly higher than after the filtered air exposure (P < 0.05). There was a significant correlation between SP and 8-epi-PGF2 alpha concentrations in the AL fluid (r2 = 0.89 and P < 0.05). There were no changes in C5a in either compartment or any of the mediators in the plasma samples. These results extend previous results from animal studies suggesting that ozone's mechanism of action is through an oxidative reaction resulting in a decreased activity of NEP in the airways with a subsequent increase in the concentration and activity of SP.
Hazbun
M E
ME
Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas 77030.
Hamilton
R
R
Holian
A
A
Eschenbacher
W L
WL
D000328:Adult; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D015926:Complement C3a / Q000378:metabolism; D015936:Complement C5a / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D010126:Ozone / Q000494:pharmacology*; D013373:Substance P / Q000378:metabolism*
C075750:8-epi-prostaglandin F2alpha; D013373:Substance P; D010126:Ozone; D015926:Complement C3a; D015936:Complement C5a; D015237:Dinoprost